Drug Criteria & Outcomes: In the Pipeline
• Medarex has announced that its licensee, Novartis Pharma AG, has commenced Phase I clinical trials of a fully human antibody product candidate for the treatment of autoimmune disease.
• Oncolytics Biotech has resumed enrollment in the Phase I component of its clinical study examining the use of Reolysin, its formulation of the human reovirus, in the treatment of recurrent malignant glioma.
• Sangart has initiated its Phase Ib/II clinical trial for Hemospan (MP4), an oxygen transport agent, at the Karolinska Hospital in Stockholm, Sweden. This clinical trial will include 30 patients undergoing elective orthopedic surgeries.
• Repligen Corp. has announced plans to conduct a clinical trial to evaluate RG1068, synthetic human secretin, in patients with schizophrenia. The objective of the trial is to determine if the improvements in social interaction found in a Phase II study of secretin in autism can be replicated in patients with schizophrenia who have significant social deficits.
• Isis Pharmaceuticals has initiated a Phase I clinical trial of ISIS 113715 for Type 2 diabetes. ISIS 113715 is a second-generation antisense drug designed to improve defective insulin signaling by targeting the gene PTP-1B.
• The FDA has granted investigational drug VG1000, manufactured by Virogenomics, orphan drug status for the treatment of multiple sclerosis.
• Hybridon has initiated a Phase I clinical trial of HYB2055, the company’s second-generation immunomodulatory oligonucleotide, in patients with malignant solid tumors.
In the PipelineSubscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.